Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04609904 · ClinicalTrials.gov registry record · Phase 3
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,187
- Enrollment target
NCT04609904 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,187 participants.
The verdict
NCT04609904, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,187 participants
- Enrollment target
Study Summary
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
Interventions
- DRUG BGF MDI 320/14.4/9.6 μg
- DRUG BFF MDI 320/9.6 μg
- DRUG BGF MDI 320/28.8/9.6 μg
- DRUG BFF pMDI 320/9 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,187 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2025-03-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04609904
The ClinicalTrials.gov registry entry for NCT04609904 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BGF MDI 320/14.4/9.6 μg is the first listed.
NCT04609904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04609904 about?
NCT04609904 is a clinical study titled "Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)". This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
What is the current status of trial NCT04609904?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,187 participants. The study started on 2021-03-01. Estimated completion is 2025-03-20.
What interventions are being tested in trial NCT04609904?
The interventions under investigation include: BGF MDI 320/14.4/9.6 μg (DRUG), BFF MDI 320/9.6 μg (DRUG), BGF MDI 320/28.8/9.6 μg (DRUG), BFF pMDI 320/9 μg (DRUG).
Who is sponsoring clinical trial NCT04609904?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.